25.86
-0.85(-3.18%)
Currency In USD
| Previous Close | 26.71 |
| Open | 26.85 |
| Day High | 26.97 |
| Day Low | 25.83 |
| 52-Week High | 31.77 |
| 52-Week Low | 11.75 |
| Volume | 786,462 |
| Average Volume | 1.8M |
| Market Cap | 3.17B |
| PE | -76.06 |
| EPS | -0.34 |
| Moving Average 50 Days | 27.86 |
| Moving Average 200 Days | 20.2 |
| Change | -0.85 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $1,186.24 as of February 16, 2026 at a share price of $25.86. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 5 years ago, it would be worth $767.59 as of February 16, 2026 at a share price of $25.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
GlobeNewswire Inc.
Jan 26, 2026 1:00 PM GMT
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on Janua
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
GlobeNewswire Inc.
Jan 22, 2026 9:00 PM GMT
Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026